New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ranitidine hydrochloride 167.5mg equivalent to ranitidine 150 mg - film coated tablet - 150 mg - active: ranitidine hydrochloride 167.5mg equivalent to ranitidine 150 mg excipient: castor oil colloidal silicon dioxide croscarmellose sodium hypromellose e-15 iron oxide yellow isopropyl alcohol magnesium stearate microcrystalline cellulose purified talc   purified water titanium dioxide - long lasting relief from acid indigestion, heartburn and symptoms resulting from excess stomach acid.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ranitidine hydrochloride 167.5mg equivalent to ranitidine 150 mg - film coated tablet - 150 mg - active: ranitidine hydrochloride 167.5mg equivalent to ranitidine 150 mg excipient: castor oil colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow isopropyl alcohol magnesium stearate microcrystalline cellulose purified talc   purified water titanium dioxide - is indicated for the treatment of duodenal ulcer, and benign gastric ulcer, including that associated with non-steroidal anti- inflammatory agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ranitidine hydrochloride 335 equivalent to ranitidine 300 mg - film coated tablet - 300 mg - active: ranitidine hydrochloride 335 equivalent to ranitidine 300 mg excipient: castor oil colloidal silicon dioxide croscarmellose sodium hypromellose e-15 iron oxide yellow isopropyl alcohol magnesium stearate microcrystalline cellulose purified talc   purified water titanium dioxide - long lasting relief from acid indigestion, heartburn and symptoms resulting from excess stomach acid.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ranitidine hydrochloride 335mg equivalent to 300 mg ranitidine - film coated tablet - 300 mg - active: ranitidine hydrochloride 335mg equivalent to 300 mg ranitidine excipient: castor oil colloidal silicon dioxide croscarmellose sodium hypromellose e-15 iron oxide yellow isopropyl alcohol magnesium stearate microcrystalline cellulose purified talc   purified water titanium dioxide - indicated for the treatment of duodenal ulcer, and benign gastric ulcer, including that associated with non-steroidal anti- inflammatory agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ranitidine hydrochloride 167.5mg equivalent to ranitidine 150 mg - film coated tablet - 150 mg - active: ranitidine hydrochloride 167.5mg equivalent to ranitidine 150 mg excipient: castor oil colloidal silicon dioxide croscarmellose sodium hypromellose e-15 iron oxide yellow isopropyl alcohol magnesium stearate microcrystalline cellulose purified talc purified water titanium dioxide - symptomatic relief of heartburn, dyspepsia and hyperacidity in adults and children over 12 years.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 336 mg (equivalent: ranitidine, qty 300 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ranitidine hydrochloride, quantity: 336 mg (equivalent: ranitidine, qty 300 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; hypromellose; castor oil; iron oxide yellow; titanium dioxide; purified talc - indicated for short-term treatment of proven duodenal ulcer and gastric ulcer; maintenance treatment to reduce the risk of relapse in duodenal ulcer; maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer; treatment of gastrinoma (zollinger-ellison syndrome); short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids; maintenance treatment to reduce the risk of relapse of reflux oesophagitis; treatment of scleroderma oesophagitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ranitidine hydrochloride -